Pre Doxercalciferol

Pre Doxercalciferol is a synthetic analog of vitamin D2, which is used to treat secondary hyperparathyroidism in patients with chronic kidney disease. It is also known as 1-alpha-hydroxyvitamin D2 or 1-alpha-hydroxyergocalciferol. The drug works by binding to vitamin D receptors in the parathyroid gland, which reduces the production of parathyroid hormone (PTH). PTH is known to increase the levels of calcium and phosphorus in the blood, which can lead to complications in patients with chronic kidney disease. Pre Doxercalciferol is administered orally or intravenously, and the dosage is based on the patient's serum PTH, calcium, and phosphorus levels. The drug is metabolized in the liver and excreted in the feces and urine. Pre Doxercalciferol is contraindicated in patients with hypercalcemia, vitamin D toxicity, or hypersensitivity to the drug. The chemical structure of Pre Doxercalciferol is similar to that of vitamin D2, but it has a hydroxyl group attached to the carbon atom at position 1. This modification increases the potency of the drug, making it more effective in reducing PTH levels. Pre Doxercalciferol is a prodrug, which means that it is converted to an active form (1,25-dihydroxyvitamin D2) in the body. This active form binds to vitamin D receptors and regulates calcium and phosphorus metabolism. Overall, Pre Doxercalciferol is an important therapeutic option for managing secondary hyperparathyroidism in patients with chronic kidney disease.